GET DAILY SIGNALSIDEXX Laboratories (IDXX) Delivers +10% Revenue Growth in Q3 2026, Raises Full-Year Guidance
Key Takeaways
- Third-quarter 2026 revenue reached $1.21 billion, up 10% year over year on both a reported and organic basis.
- Diluted earnings per share (EPS) came in at $4.01, up 18%, while adjusted EPS of $3.96 beat analyst consensus of roughly $3.72.
- Companion Animal Group (CAG) Diagnostics recurring revenue grew 11% organically, led by 14% international growth.
- IDEXX raised its full-year 2026 revenue guidance to $4.74–$4.77 billion and its EPS outlook to $14.96–$15.16.
- The company modestly lowered its 2026 operating margin outlook to 32.1%–32.3%, partly reflecting acquisition-related costs.
- Shares moved higher in pre-market trading following the release as the guidance raise outweighed the margin revision.
Earnings Context and Why It Matters
IDEXX Laboratories is a global leader in veterinary diagnostics, and its quarterly results are widely viewed as a barometer of pet healthcare spending. The company's recurring, consumables-driven model has historically produced resilient growth even when clinic visit counts soften, because testing intensity and menu expansion tend to rise over time. Coming into this report, investors were watching whether demand for premium instruments and reference lab services could keep offsetting muted same-store clinical visit trends. The Q3 2026 print matters because it tests that thesis while also revealing how recent software acquisitions, including the CoVet ambient-listening platform, are affecting near-term profitability and the company's forward growth trajectory.
The Quarter in Numbers
IDEXX reported third-quarter 2026 revenue of approximately $1.21 billion, a 10% increase year over year and ahead of the roughly $1.19 billion consensus estimate. Diluted EPS was $4.01, up 18% as reported and 22% on a comparable basis. Adjusted EPS of $3.96 exceeded the analyst consensus of about $3.72.
Gross margin expanded 110 basis points to 62.9%, while reported operating margin reached 33.1%, up 100 basis points year over year. CAG Diagnostics recurring revenue grew 11% organically, supported by roughly 14% gains in international regions and nearly 10% growth in the U.S., even as U.S. same-store clinical visits declined an estimated 1.8%. The company placed 5,780 premium instruments during the quarter, including more than 1,900 IDEXX inVue Dx analyzers.
Management raised full-year 2026 revenue guidance to $4.74–$4.77 billion and EPS guidance to $14.96–$15.16. However, it revised the reported operating margin outlook to 32.1%–32.3%, incorporating costs tied to its CoVet acquisition. To put these figures in perspective, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The initial market response was positive, with IDEXX shares rising roughly 2.6% in pre-market trading following the announcement. Investors appeared to reward the revenue and earnings beat, the double-digit growth in recurring diagnostics revenue, and the upwardly revised full-year guidance. The reaction was tempered somewhat by the modest reduction in the operating margin outlook, which reflects integration costs and near-term dilution from the CoVet acquisition. Overall, sentiment leaned constructive because the results reinforced the durability of IDEXX's recurring-revenue model and its ability to grow earnings even against a backdrop of softer clinic visit trends.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether IDEXX can convert its growing installed base of premium instruments into sustained consumables and reference lab revenue. The inVue Dx platform, now approaching roughly 11,000 instruments placed, and the expanded IDEXX Cancer Dx panel are central to that effort, and their ramp will be a key driver of recurring revenue growth into 2027.
Margin execution also deserves attention. The company expects to expand operating margin beyond its revised 2026 levels over the next 12 months, but the CoVet integration, including associated integration costs and amortization, will need to be absorbed first. Management has flagged near-term EPS dilution of roughly $0.13 per share from the acquisition, so investors will monitor how quickly the software business scales toward its roughly $20 million annualized revenue run rate.
Finally, macroeconomic factors such as foreign exchange moves, inflationary cost pressures, and the pace of recovery in clinic visit volumes and pet adoption trends remain important swing factors. IDEXX has repeatedly demonstrated that diagnostics growth can outpace visit growth, but sustained margin expansion will depend on disciplined expense management and continued adoption of higher-value testing across its menu.
Integrating AI Tools into My Research
I frequently turn to Tickeron’s AI Screener when evaluating names like this one. The platform lets me quickly filter for comparable setups across the diagnostics space using technical patterns, fundamentals, and performance metrics, which helps confirm whether a stock’s momentum aligns with broader industry trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IDXX in upward trend: 10-day moving average moved above 50-day moving average on October 21, 2026
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 55 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 177 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.812) is normal, around the industry mean (65.876). P/E Ratio (46.935) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties